Our Pipeline

Unveiling the Potential of our Targeted Nucleic Acid Delivery Platform

We believe that our first-in-class targeted nucleic acid delivery platform can transform outcomes for a wide range of cancer patients through our new class of targeted apoptosis and immune modulators (TAIMs).

Our TAIM development programme is initially focused on three key receptor targets with our TAR001, TAR002 and TAR003 molecules.

Survival rates image

Our lead compound, TAR001, targets the epidermal growth factor receptor (EGFR) to deliver synthetic double-stranded RNA (dsRNA), to tumours which overexpress this receptor.

TargImmune development programme

TargImmune is on track to file an Investigational New Drug Application (IND) / Clinical Trial Application (CTA) with subsequent entry into man in first half of 2024.

TAR001 has the potential to be applied to a wide range of cancers and change the lives of a large number of cancer patients.

TargImmune Therapeutics chart